Patents Assigned to BIOLAMINA AB
-
Patent number: 12195757Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.Type: GrantFiled: August 22, 2023Date of Patent: January 14, 2025Assignee: BioLamina ABInventors: Outi Hovatta, Karl Tryggvason
-
Patent number: 11767509Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.Type: GrantFiled: December 30, 2020Date of Patent: September 26, 2023Assignee: BioLamina ABInventors: Outi Hovatta, Karl Tryggvason
-
Patent number: 11713448Abstract: Methods for producing hepatocytes from pluripotent human stem cells are disclosed herein. The stem cells are plated on a cell culture substrate comprising two laminins. The stem cells are then exposed to different cell culture mediums to induce differentiation. The resulting hepatocytes have higher metabolic capacity compared to hepatocytes cultured on different substrates.Type: GrantFiled: June 16, 2020Date of Patent: August 1, 2023Assignee: BIOLAMINA ABInventors: Louise Kristina Hagbard, Carl Gunnar Jesper Ericsson, Katherine Rachel Cameron, David Colin Hay, Stuart John Forbes, Hassan Rashidi
-
Patent number: 11236302Abstract: The present disclosure relates to methods for producing dopaminergic cells and evaluating their functionality. When pluripotent human embryonic stem cells are cultured on plates coated with laminin-111, laminin-121, laminin-521, laminin-421, or laminin-511 in cell culture medium containing a GSK3 inhibitor and a TGF-? inhibitor as well as timely administered fibroblast growth factor, desired neural cells are produced at far higher rates. Useful cell culture kits for producing such dopaminergic cells are also described herein, as are methods of using such cells for stem cell therapy.Type: GrantFiled: May 17, 2019Date of Patent: February 1, 2022Assignee: BIOLAMINA ABInventors: Agnete Kirkeby, Malin Pernilla Parmar
-
Patent number: 11155781Abstract: The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.Type: GrantFiled: November 14, 2016Date of Patent: October 26, 2021Assignee: BIOLAMINA ABInventors: Karl Tryggvason, Karl Kristian Tryggvason, Anna Domogatskaya
-
Patent number: 11001807Abstract: The present disclosure describes methods of differentiating cardiomyocyte progenitor cells and mature cardiomyocyte cells from pluripotent stem cells. The methods may include differentiating pluripotent stems cells on a substrate including (i) laminin-511 or 521 and (ii) laminin 221. The mature cardiomyocyte cells produced by the method may form a human heart muscle cell line for use in regenerative cardiology.Type: GrantFiled: July 2, 2014Date of Patent: May 11, 2021Assignees: NATIONAL UNIVERSITY OF SINGAPORE, BIOLAMINA ABInventors: Karl Tryggvason, Yan Wen Yap, Sun Yi, Kristian Tryggvason
-
Patent number: 10889801Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.Type: GrantFiled: December 3, 2013Date of Patent: January 12, 2021Assignee: BioLamina ABInventors: Outi Hovatta, Karl Tryggvason
-
Patent number: 10829733Abstract: Compositions and processes for culturing human stem cells in vitro in an undifferentiated state are disclosed. In this regard, human embryonic stem cells proliferated and maintained their pluripotency when cultured on plates coated with recombinant laminin-10 (laminin-511).Type: GrantFiled: March 17, 2010Date of Patent: November 10, 2020Assignee: BIOLAMINA ABInventors: Karl Tryggvason, Sergey Rodin, Anna Domogatskaya
-
Patent number: 10683486Abstract: Methods for producing hepatocytes from pluripotent human stem cells are disclosed herein. The stem cells are plated on a cell culture substrate comprising two laminins. The stem cells are then exposed to different cell culture mediums to induce differentiation. The resulting hepatocytes have higher metabolic capacity compared to hepatocytes cultured on different substrates.Type: GrantFiled: October 29, 2016Date of Patent: June 16, 2020Assignees: BIOLAMINA AB, THE UNIVERSITY OF EDINBURGHInventors: Louise Kristina Hagbard, Carl Gunnar Jesper Ericsson, Katherine Rachel Cameron, David Colin Hay, Stuart John Forbes, Hassan Rashidi
-
Patent number: 10344259Abstract: The present disclosure relates to methods for producing dopaminergic cells and evaluating their functionality. When pluripotent human embryonic stem cells are cultured on plates coated with laminin-111, laminin-121, laminin-521, laminin-421, or laminin-511 in cell culture medium containing a GSK3 inhibitor and a TGF-? inhibitor as well as timely administered fibroblast growth factor, desired neural cells are produced at far higher rates. Useful cell culture kits for producing such dopaminergic cells are also described herein, as are methods of using such cells for stem cell therapy.Type: GrantFiled: April 8, 2016Date of Patent: July 9, 2019Assignee: BIOLAMINA ABInventors: Agnete Kirkeby, Malin Pernilla Parmar
-
Patent number: 10240124Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.Type: GrantFiled: September 19, 2012Date of Patent: March 26, 2019Assignee: BioLamina ABInventors: Karl Tryggvason, Sergey Rodin
-
Patent number: 10138292Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.Type: GrantFiled: December 16, 2011Date of Patent: November 27, 2018Assignee: BIOLAMINA ABInventors: Karl Tryggvason, Sergey Rodin
-
Patent number: 9828630Abstract: The present disclosure relates to the use of laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. Methods of enhancing genetic diagnosis by expanding a single stem cell on laminin-521 prior to PCR amplification are disclosed herein.Type: GrantFiled: November 30, 2012Date of Patent: November 28, 2017Assignee: BIOLAMINA ABInventors: Karl Tryggvason, Kristian Tryggvason
-
Patent number: 9719066Abstract: The present disclosure is related to methods for forming a stem cell bank. The methods include obtaining a first stem cell from a multi-cell fertilized embryo, expanding the first stem cell into two or more descendant stem cells, and storing at least one of the descendant stem cells to form the stem cell bank. Also disclosed is a kit that can be used for making the stem cell bank during in vitro fertilization. If desired, the HLA serotype of the stem cells can be determined prior to storage.Type: GrantFiled: September 6, 2013Date of Patent: August 1, 2017Assignee: BIOLAMINA ABInventors: Karl Tryggvason, Kristian Tryggvason, Outi Hovatta
-
Patent number: 9534038Abstract: The present disclosure provides isolated laminin-421, methods for making recombinant laminin-421, and host cells that express recombinant laminin-421. The present disclosure also provides nucleic acid sequences encoding full length human laminin ?2 chain, expression vectors and host cells thereof.Type: GrantFiled: March 1, 2012Date of Patent: January 3, 2017Assignee: BIOLAMINA ABInventors: Karl Tryggvason, Sergey Rodin
-
Patent number: 9499794Abstract: The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.Type: GrantFiled: April 19, 2013Date of Patent: November 22, 2016Assignee: BioLamina ABInventors: Karl Tryggvason, Karl Kristian Tryggvason, Anna Domogatskaya
-
Publication number: 20150191694Abstract: The present disclosure is related to methods for forming a stem cell bank. The methods include obtaining a first stem cell from a multi-cell fertilized embryo, expanding the first stem cell into two or more descendant stem cells, and storing at least one of the descendant stem cells to form the stem cell bank. Also disclosed is a kit that can be used for making the stem cell bank during in vitro fertilization. If desired, the HLA serotype of the stem cells can be determined prior to storage.Type: ApplicationFiled: September 6, 2013Publication date: July 9, 2015Applicant: BioLamina ABInventors: Karl Tryggvason, Kristian Tryggvason, Outi Hovatta
-
Patent number: 8951799Abstract: The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, that both maintain stem cells in vitro pluripotency and enable self-renewal. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or their functional domains, in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferated and maintained their pluripotency.Type: GrantFiled: August 25, 2009Date of Patent: February 10, 2015Assignee: BioLamina ABInventors: Anna Domogatskaya, Sergey Rodin, Karl Tryggvason
-
Publication number: 20130280750Abstract: The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.Type: ApplicationFiled: April 19, 2013Publication date: October 24, 2013Applicant: BIOLAMINA ABInventors: Karl Tryggvason, Karl Kristian Tryggvason, Anna Domogatskaya
-
Patent number: 8415156Abstract: The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.Type: GrantFiled: December 16, 2011Date of Patent: April 9, 2013Assignee: Biolamina ABInventors: Karl Tryggvason, Sergey Rodin